Although FGL2 has been identified as a biomarker in various cancers, such as glioma,51, 52, 53 breast cancer,54 gastrointestinal stromal tumour55 and lung cancer,56, 57 no studies have focused on FGL2 as a prognostic and treatment biomarker in AML. This evidence concerns the gene FGL2 and breast carcinoma.